Revefenacin | |||||
---|---|---|---|---|---|
Placebo | 44 μg | 88 μg | 175 μg | 350 μg | |
D28a trough FEV1 change from baseline, mL | |||||
n | 55 | 60 | 63 | 59 | 63 |
LS mean (SE) | −32.4 (25.36) | 19.4 (24.98) | 155.0 (24.61) | 134.2 (25.07) | 138.2 (24.38) |
LS mean difference from placebo (95% CI) | NA | 51.8 (−17.3, 121.0) | 187.4 (118.8, 256.1)** | 166.6 (97.3, 236.0)** | 170.6 (101.9, 239.3)** |
D1 weighted mean FEV1(0–6h), mL | |||||
n | 69 | 66 | 68 | 70 | 70 |
LS mean (SE) | 33.3 (15.93) | 145.1 (16.57) | 193.8 (16.42) | 180.0 (16.06) | 214.9 (15.98) |
LS mean difference from placebo (95% CI) | NA | 111.7 (67.6, 155.9)** | 160.5 (116.4, 204.5)** | 146.7 (103.2, 190.2)** | 181.5 (138.1, 225.0)** |
D28 weighted mean FEV1(0–12h), mL | |||||
n | 55 | 63 | 63 | 59 | 64 |
LS mean (SE) | −32.8 (27.03) | 34.3 (26.13) | 129.8 (26.10) | 123.4 (26.88) | 143.1 (25.42) |
LS mean difference from placebo (95% CI) | NA | 67.1 (−4.9, 139.2) | 162.6 (90.5, 234.7)** | 156.2 (83.0, 229.4)** | 176.0 (104.3, 247.7)** |
D28 weighted mean FEV1(0–24h), mL | |||||
n | 54 | 59 | 63 | 59 | 62 |
LS mean (SE) | −78.1 (25.46) | 3.4 (25.21) | 87.0 (24.50) | 84.1 (24.97) | 96.3 (24.13) |
LS mean difference from placebo (95% CI) | NA | 81.5 (12.8, 150.2)* | 165.1 (97.2, 233.0)** | 162.1 (93.4, 230.8)** | 174.3 (106.5, 242.2)** |